Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson’s Disease and Comorbid Depression
Received 8 August 2019
Accepted for publication 15 January 2020
Published 31 January 2020 Volume 2020:12 Pages 23—30
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Hemalkumar B Mehta
Farid Chekani,1 Holly M Holmes,2 Michael L Johnson,1 Hua Chen,1 Jeffrey T Sherer,1 Rajender R Aparasu1
1Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX 77204-5047, USA; 2Division of Geriatric and Palliative Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA
Correspondence: Rajender R Aparasu
Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Health and Biomedical Sciences Building 2 – Office 4052, 4849 Calhoun Road, Houston, TX 77204-5047, USA
Tel +1832 842-8374
Purpose: According to the 2015 American Geriatrics Society (AGS) Beers criteria, most antipsychotics are inappropriate in Parkinson’s disease (PD) patients due to the risk of worsening Parkinsonian symptoms. This study examined the incidence and predictors of inappropriate antipsychotic use among long-term care residents with PD and comorbid depression.
Patients and Methods: This retrospective cohort study utilized 2007– 2009 Minimum Data Set (MDS) linked to Chronic Condition Warehouse (CCW) Medicare data files involving patients with PD and comorbid depression. Using a 12-month baseline and a 24-month follow-up, the study examined incidence of inappropriate atypical antipsychotics, namely asenapine, brexpiprazole, iloperidone, lurasidone, olanzapine, paliperidone, risperidone, or ziprasidone as specified in the 2015 AGS Beers criteria. Appropriate atypical antipsychotic included aripiprazole, clozapine, or quetiapine. Multivariable logistic regression was used to examine various sociodemographic and clinical factors associated with inappropriate antipsychotic use in PD based on the Andersen Behavioral Model.
Results: The incidence of atypical antipsychotic use was 17.50% (13,352/76,294) among PD patients over a 2-year follow-up. The percentage of inappropriate use among atypical antipsychotic users was 36.32%. The likelihood of inappropriate antipsychotic use was higher for patients who had dementia (OR=1.22, 95% CI: 1.12– 1.33) or Chronic Obstructive Pulmonary Disease ((OR=1.13, 95% CI: 1.03– 1.24). However, patients who were taking levodopa (OR=0.62, 95% CI: 0.57– 0.67), dopamine agonists (OR=0.90, 95% CI: 0.82– 0.98), Catechol-O-methyltransferase (COMT) inhibitors (OR=0.77, 95% CI: 0.68– 0.86), Monoamine Oxidase (MAO) inhibitors type B (OR=0.72, 95% CI: 0.60– 0.86), or amantadine (OR=0.84, 95% CI: 0.71– 0.98) were less likely to receive inappropriate antipsychotics.
Conclusion: More than one-third of PD patients used inappropriate antipsychotics among those who were treated with atypical antipsychotic medications. Various socio-demographics and clinical factors were associated with inappropriate antipsychotic use in older patients with PD. Concerted efforts are needed to reduce inappropriate atypical antipsychotic use among PD patients.
Keywords: Parkinson disease, psychotic disorders, antipsychotic agents
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]